

Request under Freedom of Information Act 2000

Request Ref: NGFOI 19/20: 032

Thank you for your request for information received at Northampton General Hospital NHS Trust (NGH) on 16/04/2019.

I am pleased to be able to provide you with the following information:

Please detail the number of Oncology patients treated¹ (either as a monotherapy or combination therapy) by your Trust with the stated therapies, during the 12 months January 2018 to December 2018 inclusive.

¹ Please indicate the number of patients (excluding clinical trial patients) treated (any patients treated, not only those for whom treatment with the therapy was initiated) with the stated active anti-cancer drug treatment(s).

		Total Number of Patients Treated:					
	Total Number of Patients Treated (regardl ess of Tumour Type)	Head & Neck Cancer	Adjuvan t Melano ma	Metasta tic Melano ma	Non- Small Cell Lung Cancer (NSCLC)	Renal Cell Carcino ma (RCC)	
Pembrolizumab (Keytruda)	0	0	0	0	0	0	
Nivolumab (Opdivo)	0	0	0	0	0	0	
Ipilimumab (Yervoy)	0	0	0	0	0	0	
Nivolumab & Ipilimumab	13	*	0	0	*	8	
Dabrafenib (Tafinlar)	0	0	0	0	0	0	
Cabozantinib (Cabometyx)	*	0	0	0	0	*	
Sunitinib (Sutent)	27	0	0	0	0	23	
Pazopanib (Votrient)	24	0	0	0	0	24	
Axitinib (Inlyta)	5	0	0	0	0	5	
Atezolizumab (Tecentriq)	5	0	0	0	*	0	
Sorafenib (Nexavar)	8	0	0	0	0	0	
Tivozanib (Fotivda)	*	0	0	0	0	*	
Cetuximab (Erbitux)	28	0	0	0	0	0	
Everolimus (Afinitor)	*	0	0	0	0	0	
Vemurafenib (Zelboraf)	0	0	0	0	0	0	







Total Number Treated (all	*	*	0	0	*	*
treatments)						

^{*} In accordance with the Freedom of Information Act, Exemption section 40 (Personal Information) has been applied. Due to the low numbers involved we have withheld the exact numbers to protect the identities of individuals.

While the Trust acknowledges that it is desirable to make information as freely available as possible the release of this information would be unfair to the individuals concerned and would contravene the rights of the individual under the Data Protection Act.

The information requested is therefore held exempt from disclosure under section 40 (Personal Information) of the Freedom of Information Act.



